As European markets continue to digest corporate earnings and geopolitical developments, key indices such as the STOXX Europe 600 have shown positive momentum, reflecting a cautiously optimistic sentiment despite broader economic concerns like the IMF's trimmed eurozone growth forecast. In this context, identifying high-growth tech stocks with promising potential involves looking for companies that can leverage technological advancements and maintain resilience amid fluctuating market conditions.
Top 10 High Growth Tech Companies In Europe
| Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
| Hacksaw |
24.17% |
25.33% |
★★★★★★ |
| 2CRSI |
25.76% |
65.41% |
★★★★★★ |
| Archos |
31.61% |
57.94% |
★★★★★★ |
| Adtraction Group |
4.79% |
101.86% |
★★★★★☆ |
| Pharma Mar |
16.75% |
29.35% |
★★★★★☆ |
| Pexip Holding |
10.80% |
21.88% |
★★★★★☆ |
| Bonesupport Holding |
23.74% |
34.48% |
★★★★★★ |
| Yubico |
10.99% |
36.21% |
★★★★★☆ |
| CD Projekt |
32.85% |
28.82% |
★★★★★☆ |
| SyntheticMR |
18.81% |
47.40% |
★★★★★☆ |
We'll examine a selection from our screener results.
argenx
Simply Wall St Growth Rating:★★★★★☆
Overview:argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across multiple international markets, with a market cap of €42.62 billion.
Operations:argenx SE generates revenue primarily from its biotechnology segment, amounting to $4.24 billion. The company focuses on developing therapies for autoimmune diseases across several key international markets, including the United States, Japan, and China.
argenx SE, a standout in the biotech sector, recently showcased its innovative approach at the 2026 American Academy of Neurology Annual Meeting. The company presented compelling data for VYVGART in treating myasthenia gravis and CIDP, highlighting its potential as a first-line treatment. These advancements are supported by a robust R&D framework, with significant investment yielding promising clinical outcomes. Financially, argenx reported a substantial increase in annual revenue to $4.25 billion for 2025, up from $2.25 billion the previous year, reflecting a growth rate of 17.4%. This financial strength is complemented by an earnings surge of 55% over the past year, outpacing industry norms and underscoring argenx's potential to reshape treatment paradigms in autoimmune diseases.
Hacksaw
Simply Wall St Growth Rating:★★★★★★
Overview:Hacksaw AB (publ) is a B2B technology platform and game development company operating in Sweden and the Czech Republic, with a market capitalization of SEK19.23 billion.
Operations:Hacksaw generates revenue primarily by providing online casino solutions and related services to gaming operators, amounting to €197.48 million. The company operates in Sweden and the Czech Republic, focusing on B2B technology platforms and game development.
Hacksaw Gaming is carving a niche in the high-growth tech landscape of Europe, particularly through strategic expansions and partnerships. Recently, the company's venture into new markets was underscored by securing an Online Gaming Service Provider license in Connecticut and launching with Bonver WIN in the Czech Republic. These moves complement a robust financial performance, with a reported revenue increase to €197.48 million and net income rising to €133.64 million for 2025. Such growth is bolstered by Hacksaw's commitment to innovation as seen in their OpenRGS platform attracting new studios like Good Times Studios, which promises fresh gaming experiences through its debut title, Avalanche. This strategy not only diversifies Hacksaw's portfolio but also enhances its competitive edge in the digital entertainment sector.
-
Click here to discover the nuances of Hacksaw with our detailed analytical health report.
-
Assess Hacksaw's past performance with our detailed historical performance reports.
Basilea Pharmaceutica
Simply Wall St Growth Rating:★★★★★☆
Overview:Basilea Pharmaceutica AG is a Swiss biotech company specializing in the development and commercialization of treatments for severe bacterial and fungal infections, with a market capitalization of CHF662.52 million.
Operations:The Swiss biotech firm, Basilea Pharmaceutica, generates revenue primarily from the discovery, development, and commercialization of innovative pharmaceutical products, amounting to CHF232.38 million. The company's focus is on addressing severe bacterial and fungal infections through its specialized treatments.
Basilea Pharmaceutica, a Swiss biopharmaceutical firm, is navigating a challenging landscape marked by a significant 48.1% dip in earnings growth over the past year, contrasting sharply with the industry average of 45%. Despite this downturn, Basilea's commitment to innovation remains robust, underscored by its R&D focus which continues to attract substantial support such as an additional $6 million from CARB-X for its pioneering antibiotic BAL2420. This funding boost not only reflects confidence in Basilea's potential to address critical health threats but also aligns with its strategic emphasis on developing treatments for high-priority pathogens. Moreover, while Basilea's recent revenue growth at 11.6% per annum surpasses the Swiss market average of 4.6%, its earnings are projected to rise at an impressive annual rate of 26.1%, suggesting potential resilience and recovery in its financial performance.
Turning Ideas Into Actions
-
Dive into all 59 of the European High Growth Tech and AI Stocks we have identified here.
-
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
-
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Ready For A Different Approach?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
-
Find companies with promising cash flow potential yet trading below their fair value .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTBR:ARGX OM:HACK and SWX:BSLN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
